Top F H
Yale J Biol Med. 1975 Jul;48(3):185-95.
Although limited almost exclusively to military trainees, acute respiratory disease (ARD) caused by adenovirus types 4 and 7 had been the leading cause of hospitalization in U.S. Army personnel. This decrease which resembles influenza in clinical manifestations led to hospitalization of as many as 50% of military trainees in midwinter and imposed a heavy burden on military hospitals and training programs. In studies undertaken from 1965 to 1970, live adenovirus type 4 and subsequently type 7 vaccines were found to be safe and immunogenic and to confer protection against type specific adenovirus ARD. For the past 5 yr. military trainees have been immunized with both adenovirus vaccines during periods of expected adenovirus disease. Since 1966, use of adenovirus vaccines has been monitored through the adenovirus surveillance program which yields weekly data on incidence and etiology of ARD in basic combat trainees. Since 1973, stable adenovirus vaccines have resulted in excellent control of adenovirus ARD. Potential problems with this immunization program are discussed.
虽然几乎仅局限于军事受训人员,但由4型和7型腺病毒引起的急性呼吸道疾病(ARD)一直是美国陆军人员住院的主要原因。这种在临床表现上类似流感的疾病导致多达50%的军事受训人员在冬季中期住院,给军事医院和训练计划带来了沉重负担。在1965年至1970年进行的研究中,发现4型活腺病毒疫苗以及随后的7型活腺病毒疫苗是安全且具有免疫原性的,并能提供针对特定型腺病毒ARD的保护。在过去5年里,军事受训人员在预计腺病毒疾病高发期都接种了这两种腺病毒疫苗。自1966年以来,通过腺病毒监测计划对腺病毒疫苗的使用情况进行监测,该计划每周提供基础战斗受训人员中ARD发病率和病因的数据。自1973年以来,稳定的腺病毒疫苗已很好地控制了腺病毒ARD。本文讨论了该免疫计划存在的潜在问题。